BLI:NSD-Berkeley Lights Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.77

Change

-0.44 (-8.45)%

Market Cap

USD 0.35B

Volume

0.94M

Avg Analyst Target

USD 17.75 (+272.12%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Berkeley Lights Inc (BLI) Stock Analysis:
Based on the Berkeley Lights Inc stock forecasts from 4 analysts, the average analyst target price for Berkeley Lights Inc is USD 17.75 over the next 12 months. Berkeley Lights Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Berkeley Lights Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Berkeley Lights Inc’s stock price was USD 4.77. Berkeley Lights Inc’s stock price has changed by +7.19% over the past week, -19.70% over the past month and -87.15% over the last year.

About

Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, includin ...Read More

Company Website : https://www.berkeleylights.com

Address : 5858 Horton Street, EmeryVille, CA, United States, 94608

Employees : 293

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 51.28

Short Ratio : 5.80

52 Week Low : 3.66

Shorted Shares : 4,758,409

200 Day Moving Average : 17.85

Shorted Shares Previous Month : 4,492,259

50 Day Moving Average : 6.00

Shares Held By Insiders : 14.84%

Short Percentage : 9.50%

Shares Held by Institutions : 77.28%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+9.49 (+1.47%)

 USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+7.45 (+3.02%)

 USD63.10B 27.38 17.74
MRNA Moderna Inc

-1.65 (-1.20%)

 USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

-7.64 (-4.81%)

 USD38.60B 3.81 1.75
RPRX Royalty Pharma plc

+0.32 (+0.80%)

 USD26.93B 26.81 14.86
SGEN Seagen Inc

+6.91 (+5.09%)

 USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
GMAB Genmab A/S

+0.06 (+0.20%)

 USD19.19B 46.16 5.06
ARGX argenx SE

-2.74 (-0.88%)

 USD16.75B N/A N/A

ETFs Containing BLI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -73.76% 10% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.76% 10% F 6% F
Trailing 12 Months  
Capital Gain -87.49% 11% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.49% 11% F 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -32.32% 6% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.32% 6% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 38.42% 72% C- 40% F
Risk Adjusted Return -84.13% 7% F 3% F
Market Capitalization 0.35B 70% C- 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 98% A+ 98% A+
Price/Book Ratio 1.23 60% D- 63% D
Price / Cash Flow Ratio -6.65 74% C 73% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -31.67% 77% C+ 31% F
Return on Invested Capital -28.72% 76% C 28% F
Return on Assets -15.08% 77% C+ 25% F
Debt to Equity Ratio 9.49% 66% D 73% C
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.80 43% F 27% F
Short Percent 9.50% 24% F 19% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.